Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with revenue projections soaring to $4.3B by 2030. Read more here.

TJH is on the MCBS working group for the European Society for Medical Oncology. Q-DT reports grants from Pfizer and consulting fees from Astellas, Bayer, Intuitive Surgical, Janssen, Novartis, and ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

NEW YORK, Sept. 20, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

according to data presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, and published concomitantly in the Journal of Clinical Oncology. Patients ...